Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Nurix

Nurix

A company developing protein homeostasis therapies for oncology, immunology, and inflammation cases

All edits

Edits on 19 Sep, 2022
Katrina-Kay Pettitt"prospector:1906:1373656"
Katrina-Kay Pettitt edited on 19 Sep, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Edits on 22 Jul, 2022
Golden AI"clean up phone number value"
Golden AI edited on 22 Jul, 2022
Edits made to:
Infobox (+1/-1 properties)
Infobox
Phone number
415-660-5320
Phone number
+14156605320
Edits on 18 Jul, 2022
Golden AI"clean up email address value"
Golden AI edited on 18 Jul, 2022
Edits made to:
Infobox (+1/-1 properties)
Infobox
Email address
IR@nurixtx.com
Email address
ir@nurixtx.com
Edits on 6 Jun, 2022
Bhupendra Solanki"Edit from table cell"
Bhupendra Solanki edited on 6 Jun, 2022
Edits made to:
Infobox (-1 properties)
Infobox
Bhupendra Solanki"Edit from table cell"
Bhupendra Solanki edited on 6 Jun, 2022
Edits made to:
Infobox (-1 properties)
Infobox
Edits on 3 Jun, 2022
N Ni
N Ni edited on 3 Jun, 2022
Edits made to:
Infobox (+2 properties)
Infobox
Legal name
Nurix Therapeutics, Inc.
Email address
info@nurix-inc.com
Full address
1700 Owens Street, Suite 205 San Francisco, CA 94158, USA
Phone number
415-660-5320
Exchange
Ticker symbol
NRIX
Email address
IR@nurixtx.com
Fax number
415-525-4200
N Ni
N Ni edited on 3 Jun, 2022
Edits made to:
Infobox (+7 properties)
Infobox
Legal name
Nurix Therapeutics, Inc.
Full address
1700 Owens Street, Suite 205 San Francisco, CA 94158, USA
Number of Employees (ranges)
100 – 249
Exchange
Ticker symbol
NRIX
Edits on 21 May, 2022
Ирина Носкова"Edit from table cell"
Ирина Носкова edited on 21 May, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Company Operating Status
Active
Edits on 17 May, 2022
Katrina-Kay Pettitt"prospector:1525:734198"
Katrina-Kay Pettitt edited on 17 May, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 16 Feb, 2022
Keeri Tramm"prospector:1225:498096"
Keeri Tramm edited on 16 Feb, 2022
Edits made to:
Infobox (+3 properties)
Infobox
Industry
Edits on 16 Jun, 2021
Erin Scherfner"prospector:332:163094"
Erin Scherfner edited on 16 Jun, 2021
Edits made to:
Infobox (+2 properties)
Infobox
Edits on 28 May, 2021
Golden AI"Infobox creation from: Wikidata data enrichment"
Golden AI approved a suggestion from Golden's AI on 28 May, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Henry Ogolla"Approved suggestion #1084339"
Henry Ogolla approved a suggestion from Golden's AI on 28 May, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Wikidata ID
Edits on 12 May, 2021
Golden AI"Funding autocalculation"
Golden AI edited on 12 May, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding type
Edits on 8 May, 2021
Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 8 May, 2021
Edits made to:
Article (+6/-6 characters)
Article

The wholly owned pipeline of Nutrix comprises of targeted protein degraders of BrutonBruton’s tyrosine kinase, is a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, which is an E3 ligase that regulates T cell activation.

Edits on 6 May, 2021
Nureni Akanji
Nureni Akanji edited on 6 May, 2021
Edits made to:
Article (+1109 characters)
Article

Nurix Therapeutics is a biopharmaceutical company that focuses on discovering, developing and commercializing small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels.

Nutrix leverages its extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, to build DELigase, which is an integrated discovery platform for identifying and advancing novel drug candidates targeting E3 ligases, a wide class of enzymes that can modulate proteins within the cell.

Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system, to selectively decrease or increase cellular protein levels.

...

The wholly owned pipeline of Nutrix comprises of targeted protein degraders of Bruton’s tyrosine kinase, is a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, which is an E3 ligase that regulates T cell activation.

Edits on 28 Mar, 2021
Golden AI"Found on funding round"
Golden AI edited on 28 Mar, 2021
Edits made to:
Infobox (+3 properties)
Infobox
Edits on 6 Oct, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 6 Oct, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding round date
May 2014
Edits on 22 Jul, 2020
Aleksander Holm
Aleksander Holm edited on 22 Jul, 2020
Edits made to:
Infobox (+8 properties)
Infobox
Email address
info@nurix-inc.com
Founded date
2012
Industry
Phone number
415-660-5320
Edits on 17 Jul, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 17 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
28,200,000
Golden logo
By using this site, you agree to our Terms & Conditions.